uniQure N.V. announced that AMT-130, its proprietary gene therapy candidate for Huntington’s disease, has received an Orphan Medicinal Product Designation (OMPD) from the European Medicines Agency. AMT-130 represents the first investigational AAV-gene therapy in Huntington’s disease to receive such designation. In October 2017 the company announced that the U.S. Food and Drug Administration granted orphan drug designation for the same indication. There are currently no approved medical treatments aimed at addressing the underlying cause of Huntington’s disease, and AMT-130 has the potential to play a role in this area of high unmet medical need. AMT-130 consists of an AAV5 vector carrying an engineered micro-RNA specifically designed to silence the huntingtin gene. The therapeutic goal is to inhibit the production of the mutant protein. Using AAV vectors to deliver micro-RNAs directly into the brain represents a highly innovative approach to treating Huntington’s disease. To qualify for OMPD in Europe a therapy must be intended for the treatment of a disease that is life-threatening or chronically debilitating and have a patient prevalence in the European Union of no more than 5 in 10,000. OMPD offers product market exclusivity for ten years in the European Union following regulatory approval, along with tax and financial incentives for companies developing medicines for such orphan indications. Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to loss of muscle coordination, behavioral abnormalities and cognitive decline, resulting in complete physical and mental deterioration over a 12- to 15-year period of time. The disease is caused by the expansion of CAG trinucleotide in exon 1 of a multifunctional gene coding for protein called huntingtin. Despite the clear etiology, there are no therapies available to treat the disease, delay onset or slow progression of a patient's decline.